Skip to main content
SpringerLink
Log in

Pazopanib has been added to the Clinical Practice Guidelines in Oncology for Kidney Cancer, following its US FDA approval last month

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. National Comprehensive Cancer Network.NCCN Guidelines for Kidney Cancer Updated to Include Pazopanib for Advanced Disease; Free Webinar Discusses Updates. Media Release: 3 Nov 2009. Available from: URL: http://www.nccn.org

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pazopanib has been added to the Clinical Practice Guidelines in Oncology for Kidney Cancer, following its US FDA approval last month. Pharmacoecon. Outcomes News 591, 9 (2009). https://doi.org/10.2165/00151234-200905910-00020

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905910-00020

Keywords

Search

Navigation